Nöbetçi Eczaneler
Innovative Service Unveiled for Genetic Embryo Analysis
A pioneering US-based company has introduced a groundbreaking service that performs genetic analyses on embryos derived through in vitro fertilization (IVF). This service predicts potential health risks and certain physical and psychological attributes of the unborn children.
This cutting-edge tool, named ‘Nucleus Embryo’, provides an option for parents to select embryos with a potentially more favorable genetic profile. This development has ignited significant debate across both medical and ethical realms.
Calculating 900 Distinct Health Conditions
The company’s proprietary software evaluates up to 20 embryos, generating risk scores for approximately 900 distinct health conditions and genetic traits. This includes the potential to identify diseases such as Alzheimer’s, diabetes, and cancer, along with predispositions for attributes like intelligence, height, body weight, and even eye color.
Armed with this information, prospective parents have the option to select embryos with the lowest risk profiles to proceed with the pregnancy. The service is priced at $5,999.
Controversy Over ‘Designer Babies’
This development has sparked intense ethical debates, with critics arguing that it advances the concept of ‘designer babies’ to a new level. Experts caution that the technology might be used not just to minimize disease risk, but also to select for intelligence or physical advantages.
Advocates for disability rights express concerns that such technology could frame disabilities as ‘undesirable’ traits or defects that need ‘correction’, thus influencing societal perceptions of disability.
